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Aims To investigate the combination of heart rate turbulence (HRT) and deceleration capacity (DC) as risk predictors in
post-infarction patients with left ventricular ejection fraction (LVEF) . 30%.
Methods
and results
We enrolled 2343 consecutive survivors of acute myocardial infarction (MI) (,76 years) in sinus rhythm. HRT and
DC were obtained from 24 h Holter recordings. Patients with both abnormal HRT (slope   2.5 ms/RR and
onset   0%) and abnormal DC ( 4.5 ms) were considered suffering from severe autonomic failure (SAF) and pro-
spectively classiﬁed as high risk. Primary and secondary endpoints were all-cause, cardiac, and sudden cardiac mor-
tality within the ﬁrst 5 years of follow-up. During follow-up, 181 patients died; 39 deaths occurred in 120 patients
with LVEF   30%, and 142 in 2223 patients with LVEF.30% (cumulative 5-year mortality rates of 37.9% and
7.8%, respectively). Among patients with LVEF . 30%, SAF identiﬁed another high-risk group of 117 patients with
37 deaths (cumulative 5-year mortality rates of 38.6% and 6.1%, respectively). Merging both high-risk groups (i.e.
LVEF   30% and/or SAF) doubled the sensitivity of mortality prediction compared with LVEF   30% alone (21.1%
vs. 42.1%, P , 0.001) while preserving 5-year mortality rate (38.2%).
Conclusion In post-MI patients with LVEF.30%, SAF identiﬁes a high-risk group equivalent in size and mortality risk to patients
with LVEF   30%.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Reduction of mortality by implantable cardioverter-deﬁbrillators
(ICDs) has been well documented by several trials in cardiac patients
with compromised left ventricular function assessed, as a rule, by low
left ventricular ejection fraction (LVEF).
1–5 Although the results of
these studies have now been projected into standard clinical practice,
a substantial problem remains because of the low sensitivity of the
criterion of reduced LVEF.
6–8 Many cardiac patients who die from
sudden cardiac death, likely preventable by prophylactic ICD implan-
tation, do not have left ventricular performance particularly compro-
mised.
6,8–10 According to current guidelines, these patients are
considered as low risk patients and are not protected by intensive
prophylactic treatment.
11,12 At present, methods for identiﬁcation
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quently, prophylactic ICD implantation (or other prophylactic
therapy) has never been tested in these patients. Hence, adequately
potent risk stratiﬁcation methods need to be ﬁrst demonstrated in
patients with preserved LVEF before any risk reduction prophylaxis
can be attempted.
Toaddressthisneed,wehaveconductedalargecohortfollow-up
study to investigate whether the assessment of abnormalities in
cardiac autonomic function makes risk stratiﬁcation feasible among
patients without seriously compromised ventricular performance.
To characterize abnormalities in cardiac autonomic function, we
deﬁned severeautonomic failure (SAF) as acombination of severely
impaired baroreﬂex function with abnormal autonomic tone. For
this purpose, we used Heart Rate Turbulence (HRT)
13 and cardiac
Deceleration Capacity (DC).
14 Although the risk prediction power
of these parameters was previously documented in independent
patient populations, the ways of combining them have not been
studied. In particular, previous studies suggested that DC might be
more useful in identiﬁcation of low-risk patients while the power
of HRT is mainly in the selection of high-risk cases. This study there-
fore investigated the deﬁnition of high risk as the combination of
mildly abnormal DC
14 (to exclude low-risk patients) with highly
abnormal HRT
13 (to select high-risk patients).
Methods
Study design, setting, and participants
Between January 1996 and March 2005, patients were enrolled into a
prospective cohort study at two centres, namely the German Heart
Centre and the Klinikum Rechts der Isar, both in Munich, Germany
(see Figure 1 for patient numbers). Eligible patients suffered from
acute myocardial infarction (MI) no more than 4 weeks before enrol-
ment, were not older than 75 years, presented in sinus rhythm, and did
not meet the criteria for secondary therapy by implantable
cardioverter-deﬁbrillator (ICD)
11 before hospital discharge for the
index MI. Of the 2343 study patients, 1455 were included in earlier
investigations
7,14 and are reported here with extended follow-up (5
vs. 2 years). At the same time, the number of primary endpoints
increased from 70 to 181.
MI was diagnosed if a patient had at least two of the following ﬁnd-
ings: chest pain for  20 min, creatine kinase-MB above the doubled
upper normal limit of our laboratory, and ST-segment elevation of
 0.1 mV in two or more limb leads or  0.2 mV in two or more con-
tiguous precordial leads at the time of admission. Diabetes mellitus was
considered present either if a patient was diagnosed and was receiving
treatment (diet, tablets, or insulin) or if a blood glucose concentration
of  11 mmol/L was found in repeated samples. The patients were fol-
lowed up for a median of 4.9 years (2.8–5.0 years). The local Ethics
Committee approved the collection of data and analysis of Holter
recordings. Since the data obtained were non-invasive and did not
exceed usual clinical management of the patients, the local Ethics
Committee decided that signed informed consent was not needed.
However, we did obtain oral informed consent.
Assessment of autonomic markers
Each patient of the study population (n ¼ 2343) underwent 24 h
Holter recording. These recordings were obtained at a median of 8
days after the index infarction (interquartile range 5–11 days). All
recordings were routinely processed using standard commercial equip-
ment (Oxford Excel Holter system, Oxford instruments; Pathﬁnder
Figure 1 Flow chart of patient selection.
ISAR-Risk trial 577700, Reynolds Medical; and Mortara Holter system, Mortara Instru-
ment) to obtain the sequence of individual RR intervals together
with the distinction of sinus rhythm beats and ventricular premature
complexes. Using these sequences, HRT and DC were calculated
using previously published technologies
13–15 that are presently avail-
able as simple add-ons to standard modern Holter systems.
Brieﬂy, HRT quantiﬁes the physiological short-term oscillation of
cardiac cycle lengths that follows spontaneous ventricular premature
complexes.
16 HRT consists typically of a brief heart rate acceleration
followed by a gradual heart rate deceleration. These HRT phases are
quantiﬁed by two numerical descriptors, HRT onset and HRT slope.
DC is an integral measure of all deceleration-related oscillation
observed over 24 h. Computation of DC is based on a novel signal
processing algorithm capable of extracting periodic components out
of non-stationary biological signals.
Consistent with previous reports, HRT onset was considered
abnormal if  0%,
13 HRT slope if  2.5 ms per RR interval,
13 and DC
if  4.5 ms.
14
Patients who exhibited these pathologies in both components of
HRT as well as in DC were considered to suffer from seriously abnor-
mal cardiac autonomic modulations. The term SAF was used to
describe this abnormality.
Left ventricular performance
In each patient, LVEF was assessed by left ventricular angiography (n ¼
1686) or biplane echocardiography (n ¼ 657) during the second week
after the index infarction. In agreement with previous reports on the
utilization of prophylactic ICDs in patients with compromised left ven-
tricular performance,
3,11 reduced LVEF was deﬁned if  30%.
Endpoints of the study
Last planned follow-up assessment was 1/2007. In cases of death, the
reason for death was veriﬁed from hospital and autopsy records,
and from either the primary physician or those witnessing the death.
An independent endpoint committee determined the mode of death.
Deaths were categorized as cardiac and non-cardiac. Cardiac deaths
were further categorized as sudden and non-sudden. Cardiac death
was deﬁned as sudden if it was
1 a witnessed death occurring within
60 min of the onset of new symptoms, unless there was an obvious
non-cardiac cause,
2 an unwitnessed death within 24 h in the absence
of pre-existing progressive circulatory failure or other causes of
death, or
3 death during attempted resuscitation. The primary endpoint
of the study was all-cause mortality within the ﬁrst 5 years of
follow-up; secondary endpoints were cardiac and sudden cardiac
death also at 5 years of follow-up. The cut-off of 5 years was
derived from the expected ICD longevity.
High-risk groups
Some patients who suffered from SAF also had LVEF  30% which made
them eligible for prophylactic ICD implantation based on the presently
available criteria. Thus, to investigate what risk stratiﬁcation by SAF
offers in addition to reduced LVEF, we considered and compared two
distinct high-risk groups, that is (i) patients with LVEF  30% and (ii)
patients with LVEF .30% and SAF. We also considered the group of
all patients with SAF, and a combination of these high-risk groups, that
is patients with either LVEF  30% or LVEF .30% and SAF.
Statistics
Continuous variables are presented as median and inter-quartile range;
qualitative data are expressed as absolute numbers and percentages.
Comparison of variables between high-risk groups (LVEF   30% or
SAF and LVEF . 30%) was performed with either a linear or logistic
model in order to adjust for differences in age and sex. Survival
curves for total mortality were estimated by the Kaplan–Meier
method
17 and compared using the two-sided log-rank test.
18 The inﬂu-
ence of SAF on total mortality was estimated with the Cox
proportional-hazards model adjusted for established risk factors, includ-
ing age  65years, presence of diabetes mellitus, history of previous MI,
arrhythmia signs on Holter ( 10 VPCs/h and/or non-sustained ventricu-
lar tachycardia on Holter) and sex. Mortality rates of both high risks
groups (LVEF   30% and SAF and LVEF . 30%) were also compared
by the Cox-model adjusted for age and sex. The proportional hazard
assumption of the various parameters was investigated by using Schoen-
feld residuals. Hazard ratios together with 95% conﬁdence limits were
calculated. Secondary endpoints (cardiac death and sudden death)
were analysed with competing risk models
19 and compared with the
procedure proposed by Gray.
20 Differences were considered statistically
signiﬁcant, if P , 0.05. Sensitivity and speciﬁcity were calculated for the
prediction of all-cause, cardiac, and sudden cardiac death in (i) patients
with LVEF  30%, (ii) patients with SAF, (iii) patients with SAF and
LVEF .30%, and (iv) patients with either LVEF   30% or .30% and
SAF (i.e. LVEF   30% and/or SAF).
21
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Results
The clinical characteristics of recruited patients are shown in
Table 1. Eighteen patients (i.e. 0.8% of the total population) were
lost to follow-up. They were censored at the date of latest contact.
................................................................................
Table 1 Characteristics of the study population
(n 5 2343)
Characteristic
Age (years) (median, IQR) 59 (51–67)
Female sex [n (%)] 456 (20)
Diabetes mellitus [n (%)] 412(18)
History of previous MI [n (%)] 261 (11)
CKmax (U/L) (median, IQR) 1189 (598–2460)
Creatinine (mmol/L) (median, IQR) 1.1 (1.0–1.3)
LVEF (%) 55 (45–62)
VPC (count/h) (median, IQR) 0.5 (0.1–3.5)
Nonsustained VT [n (%)] 156 (7)
PCI [n (%)] 2159 (92)
Thrombolysis [n (%)] 62 (3)
CABG [n (%)] 39 (2)
Aspirin [n (%)] 2298 (98)
b-Blocker [n (%)] 2210 (94)
ACE inhibitors [n (%)] 2132 (91)
Statins [n (%)] 2057 (88)
Diuretics [n (%)] 926 (40)
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; CK,
creatine kinase; IQR, inter-quartile range; LVEF, left ventricular ejection fraction;
MI, myocardial infarction; PCI, percutaneous coronary intervention; VPC,
ventricular premature complex; VT, ventricular tachycardia.
A. Bauer et al. 578During the ﬁrst 5 years of follow-up, 181 patients died (Table 2).
Only 39 (22%) of these deaths occurred in patients with LVEF
 30% (n ¼ 120; 5.1% of the total population) whereas 142
(78%) occurred in patients with LVEF . 30% (n ¼ 2223; 94.9%
of the total population). Cumulative mortality curves of patients
stratiﬁed by LVEF  30% are shown in the left panels of Figure 2.
After 5 years, cumulative mortality rates of patients with LVEF
 30% and .30% were 37.9% and 7.8%, respectively (x
2 ¼
110.1, P , 0.001).
Among patients with LVEF .30%, SAF identiﬁed 117 cases (i.e.
5.0% of the total population) as high-risk patients, out of whom 37
died during the ﬁrst 5 years of follow-up. Cumulative mortality
curves of these patients are shown in the right panels of Figure 2.
After 5 years of follow-up, cumulative mortality rates of patients
with and without SAF were 38.6% and 6.1%, respectively (x
2 ¼
134, P , 0.001). If one of the SAF components, i.e. either DC or
HRT, was abnormal, the corresponding cumulative mortality rate
was 9.5%; if neither component was abnormal, the cumulative
mortality rate was 4.0%. On multivariable analysis (adjusted for
age, presence of diabetes mellitus, history of previous MI, arrhyth-
mia on Holter and sex), SAF yielded a hazard ratio of 4.6 [95%
conﬁdence interval (CI) 3.1–7.0] (P , 0.001).
There was no signiﬁcant difference between the mortality rates
of both high-risk groups adjusted for age and sex (SAF and LVEF .
30% vs. LVEF   30%; hazard ratio of 0.83 (95% CI 0.52–1.32).
Similar ﬁgures were observed for cardiac death (relative risk ¼
0.88, 95% CI 0.51–1.52) and sudden cardiac death (relative
risk ¼ 0.93, 95% CI 0.42–2.08). Merging of the two high-risk
groups, i.e. considering patients with either LVEF   30% or
LVEF . 30% and SAF, led to an increase in sensitivity (Table 3),
while maintaining a high 5-year mortality rate at 38.2%.
Compared to patients with LVEF   30%, patients with SAF and
LVEF . 30% were older (68 vs. 62 years) and more often of female
sex (32% vs. 12%) (Table 4). After adjustment for age and sex stat-
istically signiﬁcant differences between both high-risk groups were
observed for prescription of diuretics (61% vs. 83%) and creatine
kinase (1.257 vs. 2.269 U/L).
Discussion
In this population, SAF identiﬁes high-risk post-MI patients among
those with LVEF .30%. The size and risk-proﬁle of the group of
patients with LVEF.30% and SAF are practically identical to
those of the high-risk group deﬁned by reduced LVEF. This is
not only true for total mortality but also for cardiac and sudden
cardiac mortality.
Although risk stratiﬁcation based purely on LVEF identiﬁed only
approximately one-quarter of the patients who died during
follow-up, combination of LVEF   30% with LVEF . 30% and
SAF identiﬁed approximately one-half of them. At the same time,
speciﬁcity was unaffected. It is thus likely that prophylactic ICD
treatment in patients with LVEF . 30% and SAF would be no
less efﬁcacious than in patients with LVEF   30%. ICD
therapy might actually be even more effective in patients with
LVEF . 30% and SAF since these patients are less prone to
deaths from pump failure which restricts the beneﬁt offered by
ICD.
22,23
There are good reasons to combine DC with HRT when deﬁn-
ing SAF. Although both these parameters reﬂect cardiac auto-
nomic modulations, HRT expresses reﬂex reaction to the cardiac
rhythm to distinct disturbance by isolated ventricular premature
beat.
13,24,25 On the contrary, DC integrates all the regulatory pro-
cesses that slow heart rate on a beat-to-beat basis thus expressing
an overall status of the autonomic, predominantly vagal
balance.
14,15 Both these facets of autonomic assessment are
reasonably independent each of the other which facilitates
making their combination such a strong risk predictor. (Note the
difference between cumulative mortality rates of 38.6% and 9.5%
when both HRT and DC were abnormal, and when only one
factor was abnormal, respectively.).
A number of other risk factors have been reported to differen-
tiate between high- and low-risk survivors of MI independently of
LVEF (e.g. heart-rate proﬁle of post-exercise recovery,
26,27 non-
linear dynamics, detrended ﬂuctuation analysis,
28 T wave alter-
nans,
29–32 electrophysiological testing,
33,34 etc.). With some of
these factors, however, the reported sensitivities and speciﬁcities
among patients with preserved LVEF are rather low. Other
reported risk factors appear more viable. For instance, similar
data to our ﬁndings were reported with T wave alternans
(although with a smaller population and fewer events).
35 Possibly,
combinations of T wave alternans with HRT and DC would
improve risk prediction in this population even further.
36
Moreover, in contrast to the other techniques,
37 SAF assess-
ment requires only a Holter recording to be obtained in post-
infarction patients and is thus not limited only to patients who
tolerate a speciﬁc provocative investigation (e.g. patients who
can exercise for the assessment of T wave alternans and/or post-
exercise heart rate recovery).
...............................................................................................................................................................................
Table 2 Endpoints at 5 years
Group Total All-cause deaths Cardiac deaths Sudden cardiac deaths Death not speciﬁed
LVEF   30% 120 39 29 12 3
SAF 152 52 40 16 3
LVEF . 30% and SAF 117 37 27 14 3
Others (¼LVEF . 30% and no SAF) 2106 105 48 29 8
Total 2343 181 104 55 14
LVEF left ventricular ejection fraction; SAF severe autonomic failure.
ISAR-Risk trial 579The clinical efﬁcacy of ICD implantation in patients with LVEF .
30% and SAF needs to be prospectively tested. Since the incidence
and mortality rates are equal to those in patients with LVEF   30%
in whom successful ICD trials exist,
1–3 such prospective studies
appear fully viable.
The cumulative mortality of patients with SAF and LVEF . 30%
constantly increased over the observation period and did not satu-
rate. In other words, patients with LVEF . 30% and SAF continue
to be at increased risk even if surviving the ﬁrst years after MI.
Thus, these patients would probably beneﬁt from ICD prophylaxis
even late after MI.
Intentionally, we did not compare primarily patients with
LVEF   30% with all patients with SAF. Those patients who have
both compromised LVEF and SAF are eligible for prophylactic
ICD implantation according to present guidelines and we are not
suggesting that SAF should compete with these guidelines. (In
our population, we have not found any practically viable criterion
that would allow excluding patients with LVEF 30% from ICD
Figure 2 Kaplan–Meier curves of all-cause mortality, cardiac mortality and sudden cardiac death for all patients (n ¼ 2343) stratiﬁed by left
ventricular ejection fraction (LVEF; left panels), for all patients (n ¼ 2343) stratiﬁed by presence of severe autonomic failure (SAF; middle
panels) and for patients with LVEF .30% (n ¼ 2223) also stratiﬁed by presence of SAF (right panels). The number of patients of the individual
groups involved in the analyses at 0, 1, 2, 3, 4, and 5 years are shown under the graphs (the same numbers apply to all three end-points). The
top and the bottom row corresponds to the upper and bottom Kaplan–Meier curve respectively.
A. Bauer et al. 580prophylaxis—data not presented here.) Rather, we show that SAF
identiﬁes a group with considerable high risk among those patients
who are not covered by present guidelines on primary ICD
prophylaxis.
The strong predictive power of SAF was conﬁrmed by further
analyses the details of which are beyond the scope of this text.
Among others, while a number of conventional measures of heart-
rate variability (HRV) were signiﬁcant predictors of mortality, SAF
yielded the strongest relative risk both uni- and multivariably inde-
pendent of the cut-off values of conventional HRV measures. Also,
the SAF components, i.e. HRT and DC were signiﬁcant and inde-
pendent multivariable predictors.
Several limitations of our study need to be recognized. We
enrolled patients younger than 76 years. Therefore, our ﬁndings
cannot be extrapolated to older post-infarction patients. More-
over, SAF assessment is restricted to patients presenting in
sinus rhythm and thus not applicable for instance to patients
with atrial ﬁbrillation which is known to be associated with
increased mortality risk including risk of sudden death.
38 Holter
recordings were obtained at median of 8 days after index infarc-
tion which might trigger a question of reproducibility. Neverthe-
less, previous publications on HRT
13,39,40 and DC
14 showed that
the power of SAF components was maintained also in popu-
lations that collected post-infarction Holter recordings at differ-
ent times. Our enrolment spanned almost 10 years during
which some advances in acute treatment have been made.
More detailed analysis of our data (not presented here) does
not show any differences in these ﬁndings between earlier and
later parts of the population. Since it is difﬁcult to distinguish
between life saving ICD therapy and other ICD interventions,
we did not include ICD therapy into study endpoints. As seen
in Table 4, the numbers of patients with effective ICD therapy
were small (only 4% of patients with LVEF  30% experienced
ICD therapy while surviving the follow-up) and including the
ICD interventions into endpoints (analysis not presented here)
did not change the principal results. The threshold of LVEF  
30% and .30% was prospectively selected when designing this
study. However, the results are not dependent on this selection.
When re-analysing the data for high-risk groups of LVEF  35%
vs. .35% and SAF, the results were practically identical. A frac-
tion of the data in our study was included in earlier investi-
gations.
7,14 However, the present study is based on much larger
data collection with substantially increased follow-up period in
which the number of endpoints was more than doubled. To
test the consistency of our data, we analysed the previously
used and the new data separately and conﬁrmed that the
results are fully independent of the original publications (analysis
not presented here). Finally, although cohort studies of this
kind characterize risk groups, they cannot replace intervention
trials.
In spite of these limitations, the results of our cohort study are
sufﬁciently robust to indicate that the autonomic markers should
be strongly considered in future cardiac prophylaxis. Assessment
of SAF after acute MI is presently readily available.
...............................................................................................................................................................................
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Table 3 Positive and negative predictive accuracies, sensitivities and speciﬁcities for prediction of all-cause mortality,
cardiac mortality, and sudden cardiac death by high-risk groups
LVEF   30% SAF SAF (in LVEF . 30%) LVEF   30% or LVEF . 30% and SAF
Total count 120 152 117 237
Prediction of all-cause mortality at 5 years
All-cause deaths 39 52 37 76
Positive predictive accuracy (%) 37.9 39.9 38.6 38.2
Negative predictive accuracy (%) 92.2 92.8 93.9 93.9
Sensitivity (%) 21.1 28.2 26.0 42.1
Speciﬁcity (%) 96.5 95.7 96.5 93.1
Prediction of cardiac mortality at 5 years
Cardiac deaths 29 40 27 56
Positive predictive accuracy (%) 27.6 29.9 27.1 27.3
Negative predictive accuracy (%) 95.9 96.4 97.2 97.2
Sensitivity (%) 27.1 37.2 34.8 52.9
Speciﬁcity (%) 96.1 95.2 96.0 92.2
Prediction of sudden cardiac death at 5 years
Sudden cardiac deaths 12 16 14 26
Positive predictive accuracy (%) 12.0 11.6 13.4 12.8
Negative predictive accuracy (%) 97.7 97.8 98.3 98.3
Sensitivity (%) 22.1 27.1 30.7 46.6
Speciﬁcity (%) 95.4 94.1 95.3 90.9
LVEF, left ventricular ejection fraction; SAF, severe autonomic failure.
ISAR-Risk trial 581Supplementary material
Supplementary material is available at European Heart Journal
online.
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Table 4 Comparison of high-risk groups
Characteristic LVEF   30% SAF and LVEF . 30% P-value
n 120 117
LVEF (%) (median, IQR) 25 (21–28) 46 (39–56) ,0.0001
Age (years) (median, IQR) 62 (55–68) 68 (60–72) ,0.0001
Female sex [n (%)] 14 (12) 37 (32) ,0.0001
P-values adjusted for age and sex
Diabetes mellitus [n (%)] 26 (22) 37 (32) 0.349
History of previous MI [n (%)] 34 (28) 20 (17) 0.029
CKmax (U/L) (median, IQR) 2269 (952–5139) 1257 (510–2455) ,0.0001
Creatinine (mg/dL) (median, IQR) 1.3 (1.1–1.5) 1.2 (1.0–1.4) 0.316
VPC (count/h) (median, IQR) 5 (1–27) 7 (2–40) 0.700
Non-sustained VT [n (%)] 22 (18) 18 (15) 0.748
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